2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112715
    ATP synthase inhibitor 1 1023043-30-2 99.56%
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels.
    ATP synthase inhibitor 1
  • HY-145608
    Zilurgisertib 2173389-57-4 98.25%
    Zilurgisertib (INCB-000928; NBU-928) is a selective ALK2 inhibitor with an IC50 value of 15 nM. Zilurgisertib inhibits SMAD1/5 phosphorylation with an IC50 value of 63 nM. Zilurgisertib inhibits hepcidin production and improve anemia. Zilurgisertib can be used in melanoma research.
    Zilurgisertib
  • HY-19867A
    Burixafor hydrobromide 1191450-19-7 98.0%
    Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses.
    Burixafor hydrobromide
  • HY-P2141A
    TRV-120027 TFA 99.69%
    TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling. TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment.
    TRV-120027 TFA
  • HY-103265B
    ARL67156 trisodium hydrate ≥99.0%
    ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma.
    ARL67156 trisodium hydrate
  • HY-17503AS
    Metoprolol-d7 hydrochloride 1219798-61-4 99.71%
    Metoprolol-d7 (hydrochloride) is the deuterium labeled Metoprolol. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol-d7 hydrochloride
  • HY-B0185S1
    Lidocaine-d10 851528-09-1 99.58%
    Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine-d10
  • HY-18660
    Ciraparantag 1438492-26-2 98.0%
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag
  • HY-108286
    Talinolol 57460-41-0 99.64%
    Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity.
    Talinolol
  • HY-145733
    DI-1859 2247061-09-0 99.62%
    DI-1859 is a potent, selective and covalent inhibitor of DCN1. DI-1859 inhibits neddylation of cullin 3 in cells at low nanomolar concentrations. DI-1859 induces a robust increase of NRF2 protein, a CRL3 substrate, in mouse liver and effectively protects mice from acetaminophen-induced liver damage.
    DI-1859
  • HY-B1751B
    Quinine sulfate 549-56-4
    Quinidine sulfate is an antiarrhythmic agent. Quinidine sulfate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine sulfate is also a K+ channel blocker with an IC50 of 19.9 μM. Quinidine sulfate can be used for malaria research.
    Quinine sulfate
  • HY-112307A
    (Rac)-1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol sodium 124011-52-5 99.97%
    (Rac)-1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol (sodium) is an anionic phospholipid, can be studied for drug delivery and the synthesis of liposomes. 1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol-containing liposomes can induce Tregs that are specific for the liposomes’ cargo. 1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol is taken up by antigen-presenting cells mediated via complement component 1q (C1q).
    (Rac)-1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol sodium
  • HY-139400A
    Pociredir hydrochloride 2490676-19-0 99.89%
    Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia.
    Pociredir hydrochloride
  • HY-12246
    XEN445 1515856-92-4 99.85%
    XEN445 is an endothelial lipase (EL) inhibitor with an IC50 of 0.237 uM. It has excellent ADME and PK activity and can increase the concentration of high-density lipoprotein cholesterol in mouse plasma.
    XEN445
  • HY-13527
    LY310762 192927-92-7 98.68%
    LY310762 is a selective 5-HT1D receptor antagonist (Ki=249 nM) with a weak affinity for 5-HT1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of 5-HT
    LY310762
  • HY-14950
    Dalcetrapib 211513-37-0 99.19%
    Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively.
    Dalcetrapib
  • HY-15404
    Darusentan 171714-84-4 98.67%
    Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors. Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM.
    Darusentan
  • HY-32883
    2,4-Difluorophenylboronic acid 144025-03-6 ≥98.0%
    2,4-Difluorophenylboronic acid is an intermediate. 2,4-Difluorophenylboronic acid can be used to synthesize dual FGFR and VEGFR inhibitors. 2,4-Difluorophenylboronic acid can be used in the research of angiogenesis and cancer.
    2,4-Difluorophenylboronic acid
  • HY-B0310
    Nizatidine 76963-41-2 99.68%
    Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models.
    Nizatidine
  • HY-B1014
    Acenocoumarol 152-72-7 ≥98.0%
    Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase.
    Acenocoumarol
Cat. No. Product Name / Synonyms Application Reactivity